Through a rights issue, Immunovia is raising SEK 64 million in capital. Joining me here to present the company and tell us more about its ongoing commercialization is Jeff Borcherding, who is the CEO of the company. Welcome.
Thank you very much. I appreciate it.
You will give a presentation, and then I'll return to ask some questions. Without further ado, I'll hand over the word.
Thank you very much. I'm excited to talk with you about Immunovia and our mission to improve pancreatic cancer survival through early detection in high-risk individuals. Immunovia is a high-growth company, and we have strong momentum, and I want to tell you a little bit more about the company today and the reasons why I'm so excited about what's ahead for Immunovia and our product, the PancreaSure test. At Immunovia, we're focused on a high-stakes, unsolved clinical problem. How do you detect pancreatic cancer early enough to make a difference for the people who get the disease? This is a significant market opportunity in terms of the size and the number of people who are at high risk. We have developed a very accurate blood test called PancreaSure in order to detect pancreatic cancer early.
We launched that test in September of 2025 in the United States, and we've built very strong commercial momentum since that launch. We'll also talk a little bit about the financial opportunity that's offered by the PancreaSure test and why we're so optimistic about the future of the company financially as well. I mentioned that we're focused on a high-stakes problem, and that problem is, how do you diagnose pancreatic cancer early? Today, pancreatic cancer is the most deadly of all of the major cancers, and the reason is simple. We simply diagnose cancer too late. If you look at the chart on the top of the right-hand side of this slide, you can see that most of the time when we diagnose pancreatic cancer today, we're diagnosing the disease when it's already at a distant stage, meaning it's already spread well beyond the pancreas.
When that's the case, if you look at the chart on the bottom, you can see that the five-year survival rate is incredibly low. Only 3% of people will survive for five years with pancreatic cancer that has spread throughout their body. We need to diagnose the disease earlier. If we do that, you can see the survival rate increases to 42% if we can diagnose the cancer when it's still in the pancreas. In fact, we can diagnose it at stage 1A, we can see survival rates of well over 80%. This is a significant market opportunity. There are a number of different types of people who are at high risk for pancreatic cancer.
Those include people that have family history of the disease, people who have genetic mutations that put them at risk, or people who have pancreatic cysts, which are small growths on their pancreas that sometimes turn out to be cancerous. In addition, we know that there's an opportunity to detect cancer in people who don't fit into those high-risk categories, and we're starting to use AI and work with our key opinion leaders in the space to be able to identify those people who seem to have early warning signs of cancer that might not be picked up yet. They might not be the kind of symptoms that lead to diagnosis, but if we can get them a test early in that process, we can diagnose the cancer early. We developed PancreaSure to address this opportunity.
PancreaSure is a test of five biomarkers where we essentially do a simple blood test. We look at the different levels of these five biomarkers, and using our custom algorithm, we can then say, "Do we believe that this patient might in fact have cancer?" If so, they need to be seen by a specialist for a diagnosis of pancreatic cancer. As I mentioned, this test gives a simple positive or negative result, and that allows physicians to make clear decisions quickly. We've studied the test extensively. You can see details here on three of the studies that we've done. These are studies where we looked at people who gave blood after being diagnosed with pancreatic cancer and compared those blood samples to people who are at high risk but don't have pancreatic cancer.
You can see that there's a large number of samples that we looked at in these studies, and we looked at them across different stages of pancreatic cancer. Most importantly, we looked at stage 1 and 2 disease to make sure that the PancreaSure test could detect the cancer early. Here you see the results of the two studies where we were looking at that early-stage detection. In the CLARITI study and in the VERIFI study, we showed sensitivity of 77.6%. That means that when we tested a blood sample from someone who had pancreatic cancer in that early stage 1 and stage 2, we were able to detect it more than three out of four times. In addition, the test showed very good specificity at 92%. Specificity basically means that you avoid a false positive.
We don't want to give someone a positive result if in fact they don't have cancer. What you can see is that with specificity of 92%, we had a very small false positive rate of less than 8%. Let's put this in context. What does it mean relative to how pancreatic cancer is detected today? People who are at high risk of pancreatic cancer will be undergoing imaging on an annual basis. That might be done with endoscopic ultrasound, they could have an MRI, or even a CT scan. You can see here on the left-hand side is the data that I just shared with you from the PancreaSure test, and on the right-hand side is data on the accuracy of those imaging approaches to detecting pancreatic cancer.
What you can see is that particularly for MRI and CT, the sensitivity of those approaches is only about 50%. That means that if you've got stage 1 or stage 2 pancreatic cancer and you have an MRI, there's a 50% chance that your clinician's going to miss that cancer. So we feel very good about the accuracy that we have with the PancreaSure test, especially because this is a blood test. It's a lot easier, it's a lot more convenient, and it's less expensive than doing some of these imaging-based approaches. One of the things that's really important about the PancreaSure test is the fact that it can detect pancreatic cancer early. You see here the results broken out by stage of cancer, and I want to point out at stage 1, we detect 75.7% of stage 1 pancreatic cancers with the PancreaSure test.
That is an incredible level of sensitivity, and it's really the key differentiator for the PancreaSure test. When we look at PancreaSure and we compare that to other blood tests that are used to diagnose pancreatic cancer or detect other cancers in a multi-cancer test, what you can see is that PancreaSure really sets itself apart based on how well it detects stage 1 disease. It offers some other benefits as well. We can turn the test around much more quickly. We can provide results in a matter of a couple days compared to a couple weeks for competing tests, and that's because the technology behind the test is a little bit simpler, and it's faster to run in the lab. That also leads to a lower-cost test, which gives us the opportunity for a better margin on the product.
I mentioned that we launched the test in the U.S. in September of 2025. We now have 36 leading high-risk surveillance programs that are using the PancreaSure test in their clinics. In fact, if you look at the top 20 rated cancer centers in the U.S., 10 of them have used the PancreaSure test since launch. You can see some of the groups here that are using the test. I am very excited about the fact that we have a mix of both top academic centers as well as large health systems that are reaching those individuals that might not live in the large metropolitan areas. As we think about the future, one of the things we are focused on quite a bit is making sure that not only do we drive volume of the PancreaSure test, but we drive revenue.
In order to do that, we have got to make sure that we are getting paid for the tests that we perform, and there are three different ways that we can get paid for the PancreaSure test. When we first launched, we were focused on patient pay or getting the cash directly from the people who were having the PancreaSure test. In February of 2026, we started to bill commercial insurance companies. Even though those companies had not made formal decisions to say, "We will reimburse the PancreaSure test, we consider it medically necessary," even before that, we started submitting claims under the belief that this is a clear clinical need and we have good performance with the PancreaSure test. Even without that formal coverage decision in place, we believe that we can get reimbursement, and we are really starting to see early signs that that is the case.
Finally, our key focus over the long term is to get coverage decisions in place. This is when those commercial insurance companies or those government payers go through our data and they make a formal determination that the test should be covered and should be reimbursed each time that it is given to a patient. As we look at how we get more of those coverage decisions in place, I am very excited to share that we recently submitted our application for coverage from Medicare. That was submitted in September, just last month. What you can see here is that we have got a number of other clinical studies that we are doing in order to continue to bolster the evidence behind the PancreaSure test.
We are partnering with top institutions, a number of different groups across the U.S., and even globally to conduct these studies with the goal to continue to generate more data on the use of the PancreaSure test to detect pancreatic cancer and to show that we can get better patient outcomes when we do that. I mentioned earlier in the presentation that we see a significant financial opportunity with the PancreaSure test, and there are really three reasons for that. First, as I mentioned earlier, this is a very large market. In the U.S., well over $2 billion total addressable market for early detection. One of the things that makes this especially attractive is that the PancreaSure test is not a one-time test. This is a test that would be done annually each year for those individuals who are at high risk.
Many of them start getting tested at around age 50, and they would be tested for decades after that. You have an opportunity for recurring revenue over time from each individual who uses the test. Then finally, I mentioned earlier that the technology behind the PancreaSure test is well-developed. That allows us to have a low cost of goods sold and gives us the opportunity to have an attractive profit margin on the test. We will talk about the fact that we are raising capital through a rights issue, and as we think about how the funds from that rights issue will be used, we are really focused on three areas. First is continuing to invest in a very targeted commercial effort, so investing in sales and marketing to continue to show the market demand for the PancreaSure test. I mentioned the clinical studies that we are conducting.
That will be a key use of the funds that we raise. Then finally, we will use some of the funds for general operations, things like running our lab in the U.S. If you would like to learn more about the rights issue, you can certainly visit us at investors.immunovia.com, where you can see much more information about the company, the PancreaSure test, and also the rights issue.
Thank you very much, Jeff. A lovely presentation.
Thank you.
I thought I could begin this Q&A by asking you a little bit more about the ambition to detect early high-risk individuals. Early detection, how does that impact survivability?
It's really, really dramatic. If you get diagnosed at stage 3 and 4, your chances of surviving are less than 5% over the next five years. Conversely, if we can identify that cancer early, for example, at stage 1A, that tumor is still very small, it's still located in the pancreas, it hasn't spread to any of the surrounding tissue. If we can identify the cancer then, we can improve that five-year survival to more than 80%.
Mm-hmm. Stage 2, what's survivability there like? Because I know that you detect there as well.
You're probably looking at somewhere around the 40% range at stage 2.
Mm-hmm. Looking at economics then, you mentioned the total addressable market that is big. Could you give us a number?
Yeah. It's about $2.5 billion in total addressable market for the PancreaSure test, and that is just looking at the people who are considered at high risk and that are covered under guidelines today. People who have family history, people who have genetic mutations, and people who have pancreatic cysts. The reality, though, is that there's additional people on top of that who could really benefit from the PancreaSure test. I mentioned that we're working with some of our key opinion leaders to look at AI-based models where they'll go into electronic health records and they'll look for individuals who are showing some of those early signs that maybe something's not quite right. We can use AI to identify that group of people and then test them with PancreaSure to see if they may in fact have pancreatic cancer.
Mm-hmm. I want to ask about AI as well, but before I do that, I still want to talk a little bit about the market. You mentioned $2.5 billion.
Yeah.
Is that realistically where you can address as well?
I think so. We see this as a fairly concentrated market, and that's just in the U.S. If you look globally, obviously there's a bigger opportunity beyond that, and certainly our focus initially is the U.S., but we have a business development effort underway to see if we can identify the right partners in China and Japan initially to take the market there, because we see substantial markets there as well.
Mm-hmm. Talk to us more about AI then. How has that introduction changed the landscape for diagnostics and, of course, also for PancreaSure?
I think in two important ways. The first is that we were able to use AI in the development of this test. When we first developed the PancreaSure test, we essentially looked at a very large number of protein biomarkers to say, "Which ones really help us to separate cancer from non-cancer blood samples?" Once we did that, we were able to use AI to say, "What's the best combination of these biomarkers to give us an algorithm, essentially an equation that we can use so that when we measure those biomarkers, it gives us the best opportunity to detect cancers that are there and at the same time avoid those false positives if the cancer's not there?" That's the first way that we've used AI.
As I mentioned, we see a lot of opportunity in using AI to identify people who might be at risk but don't fit into those neat, clean categories of high-risk individuals. We've got groups that are looking at electronic health records, where they're looking at things like lab values, changes in weight, those kinds of things, and clinical factors to identify people that really should be evaluated and tested for pancreatic cancer. They're also using it quite a bit in imaging. One of the things that's really exciting is that as imaging gets better through the use of AI, that gives us an opportunity to identify other people who should be tested with the PancreaSure test. Or if we've got a positive PancreaSure test, it gives us a better opportunity to find that cancer once we've given that positive signal.
Hmm. Are your competitors doing the same thing?
I would say that we are ahead of the field when it comes to partnering with these key opinion leaders on AI-based models. But it's a rapidly evolving field, and we see a lot of exciting things happening.
Mm-hmm. Turning to commercialization then, since the end of Q2, PancreaSure is being used in 27 centers, from 12 in Q4 2025 and 21 in Q1 of this year. I saw a figure during the presentation, 36, so I'm assuming that's where you're at today.
Yes.
Can you tell us how quickly the centers are adopting PancreaSure and how much is in the pipeline?
Sure. What we see is that we've had really good luck in getting centers to really take a look at PancreaSure and start to use it in their centers. Adoption is something that does take a little bit of time. These are large, complicated medical centers, and as a result, as you move from the trial of a test to full adoption, where they're using it every week in the clinic, what that usually requires is getting those clinics to change the protocol that they have for the monitoring of people who are at high risk.
Getting them to think through how do they want to incorporate the PancreaSure test, how are they going to use that alongside imaging or, in some cases, in place of imaging, which specific high-risk individuals are they going to use the test with, and how are they going to incorporate it into their clinic from an operations standpoint. That's really what takes some time, and that's where we have a couple of really good strategic account managers that are helping clinics work through those decisions and work through those process changes. But we're really excited about the response that we've seen to the PancreaSure test, not just the number, but the quality of the centers that are using the test. These are, as I mentioned, many of the top cancer institutes in the U.S.
Do you expect the adoption of PancreaSure by centers to be exponential or linear?
I think there's an exponential component to it, and some of that is based on the way the testing is done. You can imagine that once a center gets started, they conduct testing and they start increasing the amount of testing. As time goes on, they are retesting individuals that they've already tested before. The other thing that we allow clinics to do is that they can place future orders. Say an individual comes in today, they have an MRI, and that clinic can then say, "We want that patient to have a PancreaSure test in six months. That's not reflected in our results today, but that future order six months from now will come in, and at the same time, we're driving results between now and that six-month time period. We do see that that growth will accelerate over time.
Hmm. Is it a rule or an exception that the centers who are using PancreaSure today are recurring buyers?
I think it's certainly what we're seeing is that they're using the test quarter- over- quarter. There are some centers. We focus a lot on the high-risk surveillance centers. That's really our core focus. That's the group that we were talking about with the 36 high-risk surveillance centers. We do have some other physicians who will order a test. Maybe someone saw information about it and wanted to order the test, so they'll order that test for that particular patient. In some cases, we don't see repeat orders from them. We don't even necessarily report those clinics when we're talking about our results. Our focus is really on the ones that are our focus and where they're really trying to adopt the test.
When an order is placed, how long does it take until it's rolled out to the centers or physicians?
Once we receive the sample in our lab, we generally are providing results in about two or three days. It is a very quick turnaround time.
Mm-hmm. One of the major steps in the commercialization process is securing the Medicare coverage for PancreaSure. Could you tell us more about the process and why it is such a game-changer for companies like yourselves?
Sure. The process is such where we put together an application for coverage. That submission package largely summarizes the clinical data that supports the approval of the PancreaSure test. We have put that package together and submitted it to a group called MolDX, which is essentially a private company that has a contract with Medicare in the U.S. to conduct the evaluation of tests like ours.
As time goes on, we will continue to provide additional information to MolDX. As we get new clinical study results, we can provide that information to them. They will do a very thorough review. They will review all of our clinical studies, they will review the publications. In some cases, they do a Contractor Advisory Committee where they will bring in experts from the field and ask them questions, and then ultimately they will make a decision about the test based on the performance of the test and really how they see it playing out for the Medicare audience. For us, that Medicare coverage is really important for a few different reasons. First is the fact that it provides a really good revenue opportunity for us. Our reimbursement rate from Medicare is $897 per test. Once we get the coverage decision in place, that creates a significant opportunity for us.
The second reason that Medicare is really important is that many of the people who are getting screened for pancreatic cancer are over the age of 65, and that's the group that has Medicare coverage in the U.S. So, from a patient population standpoint, it's a meaningful part of the group that's taking the PancreaSure test. Then finally, what I would say is that other commercial insurance companies tend to look for Medicare coverage, and they see that as an important seal of approval as they're thinking about whether they want to make their own positive medical policy decisions as well.
Positive results from your ongoing ASSURE study, is that need to have or nice to have in the process?
I think that the ASSURE study is more nice to have than need to have, but it does provide, from a coverage perspective, but it provides really important information for the clinicians who are using the test. When we do clinical studies, there's often an element that's artificial about those studies, whereas the ASSURE study is a registry study, so it's looking at real-world use of the test, and that's really valuable information for physicians. So, the ASSURE study will certainly complement what we're doing in terms of our payer submissions, but I would say in some ways it's even more important for clinicians.
You've secured the billing code at a payment of $897 per test. How was that figure decided?
When Medicare makes a decision about that rate, what they do is they look at comparable tests that are in the market and they say, "What tests look like the tests that we're being asked to price?" A lot of times what they'll do is look at the technical aspects of the test. What's the complexity of the test? What are the steps involved? What's required? We provided information to that decision process. In fact, we went back and initially had to go back and say, "There's a real opportunity here for a different price." We worked with CMS to actually get to that $897 price. We feel very good about it. We feel like that's a price that really allows us to do well financially, and we feel like it's reasonable from a Medicare perspective as well.
When can investors expect this process to end, or conclude, rather?
That's a great question, and I wish I could give you a timeframe. The reality is that there is not a specific timeline that the process works under. It's not as if they have a deadline where they have to get back to us. The process can take quite a while. Our goal in making our submission was to really lay out why it's important that PancreaSure get prioritized. One of the things that takes quite a while with these reviews is that there are so many tests that are seeking approval and a coverage decision. One of the things that was important for us was to really show that this is an opportunity to make a real impact for people who are in that Medicare population.
We know that the vast majority of people who die of pancreatic cancer are on Medicare, and so to really make an impact for those individuals clinically, and also to avoid the incredible costs of pancreatic cancer, this is really a good opportunity. We've tried to lay out that case so that we can get prioritized in the list of the many tests that they're looking at.
How do you expect Medicare coverage to impact your volumes?
I think it will have some impact on our volume. Certainly, it is a question that we get from clinicians today. "Do you have Medicare coverage or do you have insurance coverage?" The reality is we've really tried to make sure that cost is not a barrier to someone getting the PancreaSure test. The key way that we do that is through a financial assistance program. That's really important for us in order to make sure that patients can afford the test. We don't want this to be something that is only available to people who have money, and at the same time, we want to make sure that clinicians have confidence that if they order the PancreaSure test, that we're doing everything we can to make the test affordable for their patients.
I think the Medicare coverage will help, but it's something that we're trying to work through now, even without that coverage in place.
Let's talk financing. You're doing a rights issue. You want to raise SEK 64 million in capital, and this is at full subscription. Why is Immunovia currently doing a rights issue, and more importantly, why now?
For us, we are at that stage of development where we are making investments in commercialization, we are making investments in clinical studies, and yet we do not yet have that significant revenue stream that allows us to fund all of those activities internally. The nature of Immunovia as a life sciences company is that the potential for the company is terrific, but you do have to go through this period where it is a time of investment rather than a time of generating significant revenue and significant profit. For us, in order to be able to continue to invest in the business, it was critical that we conduct the rights issue.
Please correct me if I am wrong, but your current burn rate is at around SEK 7 million a month. Assuming full subscription, how long would that cash balance take you, and where is Immunovia then?
Yeah. We have basically had guidance out to investors that we expect our cash burn to be about SEK 8 million-SEK 10 million per month. As you said, we have been able to manage the process so that we spend less than that. What we are looking at now is, are there continuing opportunities to manage that cash burn rate? I think as we think about how does this rights issue fund the company, part of what we need to see is how does the rights issue play out? How much do we ultimately raise? What we believe is that the initial rights issue together with the warrants that come through this, we believe that that should take us into the third quarter of 2027. As you can imagine, we have a lot of other things that we are working on to try to fund the company.
Everything from looking for grant opportunities to looking for business development opportunities where we may be able to work with partners who can infuse capital into the company. Certainly the rights issue is critically important, but we recognize that it is an expensive way to raise money, and so we are looking at some of those other ways that we can fund the company in 2027 and beyond.
Mm-hmm. Correct me if I'm wrong or interpreting you incorrectly, but Q3 2027 sounds like you're not expecting to be profitable by then.
I don't think so. I think if you look at where we have the reimbursement coming, my guess is it'll be after that, and I think that's based on just the reality that getting some of those coverage decisions in place that allow us to collect that $897 from Medicare or something fairly close to that from a commercial payer, we've still got some time before that happens. But we do, as I mentioned earlier, see revenue growing as not only we get those patient payments, but also as we start to get more and more of the commercial insurance payments.
You were talking options as well, one of them being partnerships.
Yes.
What are you primarily looking in that? Is it a commercial partner? Is it a clinical partner? What are we looking at here?
Yeah. I think our primary focus is on commercial partners. We are looking for a commercial partner in the U.S. Right now, we have a very targeted sales and marketing effort. There is an opportunity to significantly increase volume of PancreaSure if we bring on the right commercialization partner and we go from having two reps to dozens of reps or more who are selling the PancreaSure test. That's the primary focus for us. There are other opportunities to look for partnerships. One of the things that's happening in pancreatic cancer right now that is exciting is the fact that there are more therapies that are in development, and also there have been some recent successes in the clinic where you've got promising therapies for pancreatic cancer. Those groups are very eager to identify more people with pancreatic cancer earlier in the process of the disease.
We're looking at opportunities to partner with them, both on research projects, but also potentially on commercialization or as a source of funding.
Mm-hmm. Are dialogues initiated or they're ongoing? What's the status?
Yeah, the dialogues are ongoing. Particularly for those commercial partners, we've been having conversations with about a dozen potential partners for probably a couple years now. Our goal is to keep them aware of our development, aware of the good things that are happening at Immunovia, the commercial traction that we're seeing with the PancreaSure test, and our progress on reimbursement. We stay in regular contact, and our goal is to identify the right partner at the right time, and reach a deal.
Mm-hmm. Returning to the rights issue then, it's 80% covered by subscription commitments and underwriting agreements. How is that split between guarantors, investors, and of course, yourselves?
Yeah, so it's primarily through guarantors that the guarantees are in place. I will say that all of the members of the board and I are participating in the rights issue ourselves, and taking our pro-rata share, and that's important for me. I think it's important that investors know that I'm personally invested in the company, and continue to make investments in the company as we raise capital and look to fund our growth.
Mm-hmm. Jeff Borcherding, thank you very much for being here, presenting, and answering our questions.
Thank you very much.